We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Therapeutic Ultrasound System Ablates Prostate Tissue

By HospiMedica International staff writers
Posted on 22 Nov 2015
A new high-intensity focused ultrasound (HIFU) system offers an effective option for prostatic tissue ablation with a low occurrence of side effects.

The Ablatherm HIFU system is intended for treating patients with localized prostate cancer (stages T1-T2) who are not surgical candidates due to age or comorbidities, those who prefer an alternative option, or for patients who failed previous radiotherapy (RT) treatment. The system itself consists of a treatment module, a control module, and a probe with both treatment and imaging transducers. After a spinal epidural or general anesthetic (GA) is administered, the patient lies down on his right lateral decubitus and stays in this position throughout the treatment.

Image: The Ablatherm HIFU system probe (Photo courtesy of EDAP TMS).
Image: The Ablatherm HIFU system probe (Photo courtesy of EDAP TMS).

The Ablatherm HIFU probe is then introduced in the rectum, and the imaging transducer scans the prostate gland to plan robotic treatment. Once the ablation sequence is finalized, the treatment transducer emits HIFU ultrasound in the prostate gland; at the focal point—where the ultrasound waves are focused—the absorption of the ultrasound emission beam creates a sudden temperature increase, to around 85 °C, which destroys the tissue in the targeted zone. The Ablatherm HIFU system is a product of EDAP TMS (Vaulx-en-Velin, France), and has been approved by the US Food and Drug Administration (FDA).

“This clearance represents a unique opportunity for EDAP and its superior HIFU technology to penetrate the largest prostate market in the world in the same way it has emerged as the leading HIFU technology in Europe,” said Marc Oczachowski, CEO of EDAP TMS. “The pieces are in place to begin deploying Ablatherm devices in the US very quickly, and we look forward to bringing the technology to urologists as well as patients in need.”

HIFU technology is based on nonlinear acoustic mathematical optimization methods to analyze and simulate the propagation of sound in material. The information is then used to enhance the shape of an acoustic lens in such a way that that ultrasound pressure is focused precisely on the location of the tissue to be ablated, while the surrounding tissue retains as little damage as possible.

Related Links:

EDAP TMS
Link to video



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Phlebotomy Cart
TR-65J38
New
Hospital Data Analytics Software
OR Companion

Latest Surgical Techniques News

Revolutionary Robotic Surgery Combines Dual-System Technologies for Groundbreaking Prostate Procedure

Robotic-Assisted and AR Spine Surgery Enable Equally High Degree of Precision and Accuracy, Finds Study

Magnetically Driven Robotic Microscrews for Fallopian Tube Blockages to Revolutionize Infertility Treatment